Biosimilars are essential healthcare equalizers, but their regulation is overly complicated due to lobbying by makers of ...

With this partnership, they aim to enhance access to affordable treatments for patients suffering from autoimmune diseases ...

I Gedeon Richter Plc. announces today that the European Medicines Agency has accepted Richter’s marketing authorization application (MAA) for ...

Total Revenues in 2024 reached $492 million, representing a 427% increase over prior yearProduct Revenues in 2024 reached $273 million, ...

The Board of Directors of the African Development Bank (the "AfDB") has approved a EUR 15 million senior corporate loan to Minapharm Pharmaceuticals S.A.E. (Minapharm), a leading biopharmaceutical ...

Alvotech (NASDAQ: ALVO, or the "Company”), a global biotech company specializing in the development and manufacture of ...

Planegg-Martinsried, Germany - Formycon AG (FSE: FYB, “Formycon”) today published its audited consolidated financial statements for the 2024 financial year and provided an outlook for fiscal year 2025 ...

Introduction Biosimilar monoclonal antibodies (mAbs) are biologic drugs designed to be highly similar to already approved reference monoclonal ...

LAKE ZURICH, IL, USA I March 27, 2025 I Fresenius announced that the Biologics License Application (BLA) for the denosumab biosimilars Conexxence® ...

On behalf of the Board, I want to thank Marc for his invaluable contributions to AEON over the last several years and his dedication to exhaustively evaluating all opportunities for the Company to ...

Alvotech, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced the acquisition of Xbrane Biopharma AB’s (Xbrane) R&D ...

In an expert call, the brokerage addressed possibilities of pass-through of tariffs to consumers, and the feasibility of ...